GZBL(SZ:002424)2020-04-29 16:00Financial Performance - The company's operating revenue for Q1 2020 was ¥777,241,684.86, representing a 10.34% increase compared to ¥704,419,288.42 in the same period last year[8] - Net profit attributable to shareholders was ¥84,391,446.39, a decrease of 46.20% from ¥156,849,139.70 year-on-year[8] - The basic earnings per share decreased by 45.45% to ¥0.06 from ¥0.11 in the previous year[8] - The total operating revenue for the first quarter was CNY 777,241,684.86, an increase from CNY 704,419,288.42 in the previous period, representing a growth of approximately 10.3%[52] - Net profit for the current period was ¥53,666,639.79, a decrease of 60.7% from ¥136,764,951.78 in the previous period[68] - The company reported a total profit of ¥68,245,546.91, down from ¥154,006,895.33, indicating a decline of 55.7%[68] - The total comprehensive income for the current period was ¥53,666,639.79, down from ¥136,764,951.78, a decline of 60.7%[68] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,236,380,129.95, reflecting a 2.51% increase from ¥7,058,918,161.15 at the end of the previous year[8] - The total assets increased to ¥7,236,380,129.95 from ¥7,058,918,161.15, reflecting growth in both current and non-current assets[36] - The total liabilities reached CNY 2,792,008,451.35, compared to CNY 2,717,643,227.32 in the previous period, reflecting an increase of approximately 2.8%[50] - The total equity attributable to shareholders was CNY 3,737,807,035.84, up from CNY 3,684,140,396.05, showing a growth of around 1.5%[50] Cash Flow - The net cash flow from operating activities was negative at -¥51,759,676.32, an improvement from -¥94,216,042.16 in the same period last year[8] - Operating cash flow net amount improved by 45.06% to -¥51,759,676.32 from -¥94,216,042.16, due to reduced tax payments compared to the previous year[21] - Cash inflow from investment activities is CNY 459,600,000.00, with cash outflow totaling CNY 1,033,765,951.38, resulting in a net cash flow of -CNY 574,165,951.38[72] - Cash inflow from financing activities is CNY 739,400,000.00, while cash outflow is CNY 605,442,820.27, leading to a net cash flow of CNY 133,957,179.73[75] Shareholder Information - The total number of shareholders at the end of the reporting period was 69,597, with the largest shareholder holding 47.44% of the shares[12] - The company did not engage in any repurchase transactions during the reporting period[18] Expenses - Sales expenses increased by 33.73% to ¥227,274,212.85 from ¥169,948,441.75, due to expansion of sales terminals and increased market personnel costs[21] - Research and development expenses rose by 521.73% to ¥5,466,775.65 from ¥879,277.89, driven by the development of COVID-19 treatment drugs[21] - Operating costs amounted to ¥281,601,829.96, up from ¥214,413,818.77, reflecting a 31.3% increase[62] - The total operating costs for the current period were ¥648,781,615.44, compared to ¥506,563,145.79 in the previous period, reflecting a 28.0% increase[60] Other Income and Expenses - The company reported non-operating income of ¥204,284.00, which includes government subsidies and other income[8] - Other income for the current period was reported at ¥4,928,135.73, a significant increase from ¥519,576.10 in the previous period[62] - The company incurred credit impairment losses of ¥18,623,509.90, compared to ¥15,139,882.84 in the previous period, representing a 16.4% increase[65] Cash and Cash Equivalents - Cash and cash equivalents decreased by 43.71% to ¥639,942,954.46 from ¥1,136,888,409.98 due to reduced net cash inflow from operating activities and increased net cash outflow from investing activities[21] - The ending cash and cash equivalents balance is CNY 610,692,665.78, down from CNY 855,763,018.90 in the previous period[75] Audit Information - The company has not undergone an audit for the first quarter report[82]